RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aerpio Pharmaceuticals Stock

Aerpio Pharmaceuticals ROE 2025

Aerpio Pharmaceuticals ROE

0

Ticker

ARPO

ISIN

US00810B1052

WKN

A2PF28

In 2025, Aerpio Pharmaceuticals's return on equity (ROE) was 0, a 0% increase from the 0 ROE in the previous year.

Aerpio Pharmaceuticals Aktienanalyse

What does Aerpio Pharmaceuticals do?

Aerpio Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of therapy options for serious diseases. The company was founded in 2011 and is headquartered in Cincinnati, Ohio. The company works with an innovative approach to offer hope for a cure through the inhibition of a specific group of enzymes. Aerpio Pharmaceuticals specializes in the research and development of therapeutics in the field of ophthalmology and cardiovascular diseases. The company is made up of an experienced team of scientists and executives who are active in the biotechnology and pharmaceutical field. The company aims to advance the clinical development of therapeutics based on the inhibition of specific enzymes. In its quest to deliver innovative results, Aerpio Pharmaceuticals is divided into two main divisions. The first division focuses on ophthalmology and seeks to develop novel therapeutics for eye diseases such as diabetic retinopathy and macular degeneration. These diseases are characterized by excessive blood vessel formation in the eye. Aerpio Pharmaceuticals aims to combat these diseases by inhibiting enzymes and researching new possibilities. The second division deals with cardiovascular diseases such as hypertension and renal insufficiency. Inhibition of enzymes can also lead to improved functions and thus have a healing effect. Aerpio Pharmaceuticals has already achieved promising results in this area and continues to strive to bring groundbreaking active substances to the market. Aerpio Pharmaceuticals has several products in the pipeline, some of which are in advanced stages of clinical studies. The company's lead product is AKB-9778, a compound aimed at inhibiting Ras-connection proteases, which is currently being investigated in phase III studies for the treatment of diabetic retinopathy and secondary retinal vein occlusion. In addition, Aerpio Pharmaceuticals has several other products in development, including AKB-4924 for the treatment of patients with pulmonary hypertension and AKB-5169, which is in phase II studies for the treatment of renal insufficiency. To sustain its business models and advance its developments, Aerpio Pharmaceuticals has a strong financial position. The company has successfully secured financing through venture capital, stock issuances, and agreements with major pharmaceutical companies. These financial resources enable Aerpio Pharmaceuticals to fund its ongoing clinical studies, develop new products, and create the infrastructure for marketing its products. In summary, Aerpio Pharmaceuticals is a biopharmaceutical company dedicated to the research, development, and commercialization of therapy options for serious diseases. With an innovative approach focused on the inhibition of specific enzymes, the specialists are dedicated to ophthalmology and cardiovascular diseases and are researching novel therapeutics with enthusiasm, marking milestones in pharmaceutical medicine and chronic patient care. Aerpio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Aerpio Pharmaceuticals's Return on Equity (ROE)

Aerpio Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Aerpio Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Aerpio Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Aerpio Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Aerpio Pharmaceuticals stock

What is the ROE (Return on Equity) of Aerpio Pharmaceuticals this year?

The ROE of Aerpio Pharmaceuticals this year is 0 undefined.

How has the Return on Equity (ROE) of Aerpio Pharmaceuticals developed compared to the previous year?

The ROE of Aerpio Pharmaceuticals has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Aerpio Pharmaceuticals?

A high ROE indicates that Aerpio Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Aerpio Pharmaceuticals?

A low ROE can indicate that Aerpio Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Aerpio Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Aerpio Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Aerpio Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Aerpio Pharmaceuticals?

Some factors that can influence Aerpio Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Aerpio Pharmaceuticals pay?

Over the past 12 months, Aerpio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aerpio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aerpio Pharmaceuticals?

The current dividend yield of Aerpio Pharmaceuticals is .

When does Aerpio Pharmaceuticals pay dividends?

Aerpio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aerpio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aerpio Pharmaceuticals located?

Aerpio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aerpio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aerpio Pharmaceuticals from 7/16/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2025.

When did Aerpio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/16/2025.

What was the dividend of Aerpio Pharmaceuticals in the year 2024?

In the year 2024, Aerpio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aerpio Pharmaceuticals pay out the dividend?

The dividends of Aerpio Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aerpio Pharmaceuticals

Our stock analysis for Aerpio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aerpio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.